Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon -beta therapy in multiple sclerosis].

Jun-ichi Satoh1

  • 1Department of Bioinformatics and Neuroinformatics, Meiji Pharmaceutical University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 15, 2006
PubMed
Summary

Multiple sclerosis (MS) treatment with interferon-beta (IFNbeta) effectiveness varies. Identifying IFN-responsive genes (IRG) using DNA microarrays may personalize MS therapy by predicting patient response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defects in lysosomal function and lipid metabolism in human microglia harboring a TREM2 loss of function mutation.

Acta neuropathologica·2023
Same author

Inhibition of BACE1 and Amyloid-β Aggregation by Meroterpenoids from the Mushroom <i>Albatrellus yasudae</i>.

Journal of natural products·2021
Same author

Reactive astrocytes express Aggregatin (<i>FAM222A</i>) in the brains of Alzheimer's disease and Nasu-Hakola disease.

Intractable & rare diseases research·2020
Same author

Triggering Receptor Expressed on Myeloid Cell 2 R47H Exacerbates Immune Response in Alzheimer's Disease Brain.

Frontiers in immunology·2020
Same author

CELF2 regulates the species-specific alternative splicing of TREM2.

Scientific reports·2020
Same author

Microglia express TMEM119 in the brains of Nasu-Hakola disease.

Intractable & rare diseases research·2020

Area of Science:

  • Neuroimmunology
  • Genomics

Context:

  • Multiple sclerosis (MS) is an autoimmune CNS demyelinating disease influenced by genetic and environmental factors.
  • Interferon-beta (IFNbeta) therapy reduces MS activity but lacks efficacy in some patients.
  • Adverse effects and non-response necessitate alternative therapeutic strategies.

Purpose:

  • To identify IFN-responsive genes (IRG) in peripheral blood lymphocytes.
  • To explore the role of IRG in IFNbeta's biological effects and adverse reactions in MS.
  • To investigate gene expression profiles for distinct MS subgroups and predict therapeutic response.

Summary:

  • DNA microarray analysis identified key IRG, including IRF-7, IFI30, TAP1, and TNFAIP6, involved in IFNbeta's mechanisms in MS.
  • IFNbeta induces both beneficial and detrimental immune responses, influencing MS disease activity.
  • Hierarchical clustering revealed four MS subgroups with differential gene expression, disease activity, and IFNbeta response.

Impact:

  • A panel of IRG consistently upregulated in IFNbeta responders suggests their utility as biomarkers.
  • DNA microarray analysis holds promise for optimizing personalized MS treatment strategies.
  • Understanding IRG profiles can guide the development of targeted therapies for non-responding MS patients.

Related Experiment Videos